Achieving Optimal Medical Therapy Through Percutaneous Treatment of Secondary Mitral Regurgitation to Improve Outcome in Patients With HFrEF

Prior treatment

• Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the investigator.
• Currently participating in another investigational therapeutic or interventional clinical trial, or in any trial of an unapproved drug, device or procedure. Note: Subjects participating in observational studies or registries may be considered as eligible.

Other illness

• Terminal heart failure or hemodynamic instability
• Primary TR or MR, any other severe valvular heart disease
• Untreated clinically significant CAD (coronary artery disease) requiring revascularization
• Renal failure requiring dialysis
• Life expectancy \<12 months due to non-cardiac conditions
• Active endocarditis or active rheumatic heart disease or leaflets degenerated from rheumatic disease (i.e., noncompliant, perforated)
• Active infections requiring current antibiotic therapy.
• Known hypersensitivity or contraindication to procedural device which cannot be adequately managed medically.

Lab values

• LVEF \<35% and left bundle branch block with a QRS duration \>150 ms

Other

• Mitral valve orifice area \<4.0 cm² by site assessed TTE
• KCCQ score \> 80 points
• Patient is pregnant, nursing, or planning to be pregnant
• Ineligibility to consent

• Heart failure with reduced ejection fraction (HFrEF, left ventricular ejection fraction ≤40%)
• Clinically significant functional mitral regurgitation (moderate-to severe or severe MR) as defined by European Association of Echocardiography, within 90 days prior to randomization (i.e. EROA ≥0.2 cm² and/or regurgitant fraction \>30%)
• Suboptimal GDMT therapy corresponding to a GDMT score \<7 points
• Risk factor for not intensification of guideline directed medical therapy (at least one of the following):
  • Office systolic blood pressure \<120 mmHG
  • Chronic renal failure with eGFR \<60 ml/min/1.73m
  • History of acute kidney injury (AKI) at least stage 2 within the last 12 months
  • Serum Potassium ≥ 4.8 mmol/L
• Persisting symptoms equalling NYHA functional class II-IVa (ambulatory)
• Patient has had at least one HF hospitalization within 12 months and/or a NT-proBNP ≥1000 pg/ml
• Interventional cardiologist believes secondary MR can be successfully treated by an interventional approach
• The subject has been informed of the nature of the study and agrees to the study's provisions, including the possibility of randomization to the Control group, and has provided written informed consent as approved by the respective clinical site's Ethics Committee